Table 2.
Between groups analysis
| Placebo | Nutraceutical | Inference | ||||
|---|---|---|---|---|---|---|
| Mean (SD) | n | Mean (SD) | n | Difference/OR (95% CI) | p | |
| Encrustation | ||||||
| Kidney stent end | 64.73 (241.74) | 49 | 7.66 (23.69) | 50 | 57.07 (−11.1, 125.25) | 0.89 |
| Bladder stent end | 105.51 (304.99) | 49 | 30.16 (142.52) | 50 | 75.35 (−19.3, 170.00) | 0.65 |
| Sum of stent ends | 170.24 (513.58) | 49 | 37.82 (159.24) | 50 | 75.35 (−19.28, 169.99) | 0.65 |
| Maximum of stent ends | 105.69 (304.93) | 49 | 30.34 (142.49) | 50 | 132.43 (−18.62, 283.47) | 0.67 |
| Encrustation adjusted for baseline urine pH | ||||||
| Sum of stent ends | 78.34 (158.44) | 39 | 11.11 (32.97) | 37 | 67.23 (19.18, 115.29) | 0.006 |
| Encrustation adjusted for baseline urine pH, age, gender and indwelling duration | ||||||
| Sum of stent ends | 57.57 (122.09) | 39 | 18.27 (48.42) | 37 | 39.0 (2.02, 76.57) | 0.039 |
| Urine pH | ||||||
| pH reduction baseline (24 h) to day 21 | 0.39 (0.7) | 28 | 0.86 (0.78) | 32 | −0.47 (−0.85, −0.084) | 0.018 |
| pH reduction days 1–3 to day 21 | 0.17 (0.49) | 36 | 0.54 (0.58) | 36 | −0.37 (−0.62, −0.11) | 0.005 |
| pH slope | −.0061 (.013) | 40 | −.014 (0.02) | 39 | 0.008 (0.00006, 0.016) | 0.042 |
| Stent removal | ||||||
| Removal surgery time (min) | 13.8 (30.5) | 52 | 7.23 (13.5) | 52 | 0.76 | |
| Removal surgery time (adjusted, min) | 40.9 (5.8) | 52 | 9.5 (4.15) | 52 | < 0.001 | |
| N | % | n | % | Odds ratio | ||
| Stent removed at first attempt | 47 | 48.5 | 50 | 51.5 | 2.66 [0.49–14.37] | 0.44 |